Printer Friendly

CeloNova BioSciences Touts Success of Coronary Stent in Trial.

M2 PHARMA-December 12, 2014-CeloNova BioSciences Touts Success of Coronary Stent in Trial

(C)2014 M2 COMMUNICATIONS

US-based medical device company CeloNova BioSciences, Inc. said that results from a first-in-man clinical trial presented by Luc Maillard, MD PhD, at the French Cardiology Meeting, GRCI, held in Paris, France showed that its COBRA PzF coronary stent system was effective in the treatment of heart disease.

In his presentation entitled, "First-in-man experience avec le stent Cobra-PzF, utilisant un nano-coating," Maillard concluded that the COBRA PzF coronary stent system with advanced nano-thin coating of Polyzene-F polymer can be a safe and effective interventional treatment for real-world and complex patients with heart disease, CeloNova said.

The prospective, single-centre study included 100 patients, many of whom presented with multi-vessel disease, complex lesions, and co-morbidities such as diabetes, hypertension, dyslipidemia, atrial fibrillation, history of PCI, previous myocardial infarction, and more.

At six-month follow-up, results showed zero-percent stent thrombosis, zero-percent myocardial infarctions, one cardiac death due to terminal cardiac insufficiency, and three-percent Target Lesion Revascularization, leading to four-percent Major Adverse Coronary Event.

CeloNova BioSciences develops, manufactures and markets a line of interventional cardiology and endovascular products. The company's regional offices are located in Germany, France, United Kingdom, Netherlands and Austria.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:4EUFR
Date:Dec 12, 2014
Words:213
Previous Article:Kindred Healthcare prices USD1.35bn senior unsecured notes in two tranches.
Next Article:ResMed CEO Farrell Named to Zimmer Holdings Board.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters